Literature DB >> 30063093

Pulmonary hypertension in patients with 9q34.3 microdeletion-associated Kleefstra syndrome.

Volkan Okur1, Shannon Nees1, Wendy K Chung1,2, Usha Krishnan1.   

Abstract

Kleefstra Syndrome is a rare genetic disorder caused by mutations in EHMT1, Euchromatin Histone Methyl Transferase 1, or deletions encompassing EHMT1 on 9q34.3. Congenital heart defects are among the major findings in patients with 9q34.3 microdeletion/Kleefstra Syndrome along with recognizable facial appearance, developmental delay/intellectual disability including severely delayed or absent speech, hypotonia, seizures, behavioral and sleep abnormalities. Pulmonary hypertension (PH) is a rare condition associated with increased pulmonary artery and right heart pressures that can lead to right heart failure and death if untreated. PH can be idiopathic, heritable, or associated with co-morbid conditions including congenital heart disease (CHD), lung diseases and other metabolic disorders. Genetic factors play important roles in heritable and idiopathic PH development and are particularly relevant but more diverse in etiology in children. PH is also reported in some chromosomal disorders such as Down syndrome in which congenital heart defects are common; however, PH has rarely been reported in patients with 9q34.3 microdeletion/Kleefstra Syndrome. Here, we present three patients with 9q34.3 microdeletions with CHD and PH along with review of five similar cases reported in the literature and discuss the potential association of PH with Kleefstra syndrome.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  9q34.3 microdeletion; Kleefstra Syndrome; congenital heart disease (CHD); microarray; pulmonary hypertension (PH)

Mesh:

Substances:

Year:  2018        PMID: 30063093      PMCID: PMC6107394          DOI: 10.1002/ajmg.a.38852

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  19 in total

Review 1.  The role of genetics in pulmonary arterial hypertension.

Authors:  Lijiang Ma; Wendy K Chung
Journal:  J Pathol       Date:  2016-11-29       Impact factor: 7.996

Review 2.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

3.  A study to determine the prevalence of pulmonary arterial hypertension in children with Down syndrome and congenital heart disease.

Authors:  Mukti Sharma; Sanjeev Khera; Vishal Sondhi; Amit Devgan
Journal:  Med J Armed Forces India       Date:  2013-02-23

4.  Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: An imbalance in biosynthesis of thromboxane A2 and prostacyclin.

Authors:  Hiroyuki Fukushima; Kenjiro Kosaki; Reiko Sato; Tatsuhiko Yagihashi; Ryohei Gatayama; Kazuki Kodo; Takuya Hayashi; Maki Nakazawa; Takatoshi Tsuchihashi; Jun Maeda; Yoshifumi Kojima; Hiroyuki Yamagishi; Takao Takahashi
Journal:  Am J Med Genet A       Date:  2010-08       Impact factor: 2.802

5.  Characterising and predicting haploinsufficiency in the human genome.

Authors:  Ni Huang; Insuk Lee; Edward M Marcotte; Matthew E Hurles
Journal:  PLoS Genet       Date:  2010-10-14       Impact factor: 5.917

6.  Mortality and complications in 3495 children with isolated ventricular septal defects.

Authors:  Jarle Jortveit; Elisabeth Leirgul; Leif Eskedal; Gottfried Greve; Tatiana Fomina; Gaute Døhlen; Grethe S Tell; Sigurd Birkeland; Nina Øyen; Henrik Holmstrøm
Journal:  Arch Dis Child       Date:  2016-04-18       Impact factor: 3.791

7.  Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society.

Authors:  Steven H Abman; Georg Hansmann; Stephen L Archer; D Dunbar Ivy; Ian Adatia; Wendy K Chung; Brian D Hanna; Erika B Rosenzweig; J Usha Raj; David Cornfield; Kurt R Stenmark; Robin Steinhorn; Bernard Thébaud; Jeffrey R Fineman; Titus Kuehne; Jeffrey A Feinstein; Mark K Friedberg; Michael Earing; Robyn J Barst; Roberta L Keller; John P Kinsella; Mary Mullen; Robin Deterding; Thomas Kulik; George Mallory; Tilman Humpl; David L Wessel
Journal:  Circulation       Date:  2015-11-03       Impact factor: 29.690

8.  Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with Down syndrome.

Authors:  Michel Emile Weijerman; A Marceline van Furth; Maurike D van der Mooren; Miriam M van Weissenbruch; Lukas Rammeloo; Chantal J M Broers; Reinoud J B J Gemke
Journal:  Eur J Pediatr       Date:  2010-04-23       Impact factor: 3.183

9.  A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011.

Authors:  Maria Jesus Del Cerro; Steven Abman; Gabriel Diaz; Alexandra Heath Freudenthal; Franz Freudenthal; S Harikrishnan; Sheila G Haworth; Dunbar Ivy; Antonio A Lopes; J Usha Raj; Julio Sandoval; Kurt Stenmark; Ian Adatia
Journal:  Pulm Circ       Date:  2011       Impact factor: 3.017

10.  Repression of Igf1 expression by Ezh2 prevents basal cell differentiation in the developing lung.

Authors:  Laura A Galvis; Aliaksei Z Holik; Kieran M Short; Julie Pasquet; Aaron T L Lun; Marnie E Blewitt; Ian M Smyth; Matthew E Ritchie; Marie-Liesse Asselin-Labat
Journal:  Development       Date:  2015-03-19       Impact factor: 6.868

View more
  1 in total

1.  Identification of Hub Gene GRIN1 Correlated with Histological Grade and Prognosis of Glioma by Weighted Gene Coexpression Network Analysis.

Authors:  Aoran Yang; Xinhuan Wang; Yaofeng Hu; Chao Shang; Yang Hong
Journal:  Biomed Res Int       Date:  2021-11-19       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.